Financiado en parte por Abbott Laboratories, Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Regeneron Pharmaceuticals, Amarin Corporation, Daiichi-Sankyo
Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes)
Albers JJ, Slee A, O'Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO, Xu P, Marcovina SM
Journal of the American College of Cardiology · 259 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Abbott Laboratories
- Empresa
- Amgen
- Empresa
- Eli Lilly and Company
- Empresa
- Pfizer
- Empresa
- AstraZeneca
- Empresa
- Sanofi
- Empresa
- Regeneron Pharmaceuticals
- Empresa
- Amarin Corporation
- Empresa
- Daiichi-Sankyo
- Gobierno
- National Heart, Lung, and Blood Institute
- Gobierno
- NHLBI NIH HHS
- Subvenciones
- National Heart, Lung, and Blood Institute (U01 HL081649); National Heart, Lung, and Blood Institute (U01-HL-081616); National Heart, Lung, and Blood Institute (HL-081616)
Según 11 financiadores declarados.
Publicación
- Publicado
- 2013-08-21 · J Am Coll Cardiol · vol. 62 · número 17 · págs. 1575–1579
- Editorial
- Elsevier BV
- Citado
- 318 citas · más que el 100% de estudios similares · 27.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 11 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Diabetes, Cardiovascular Risks, and Lipoproteins · Cholesterol and Lipid Metabolism
- Palabras clave
- apolipoprotein A-I, apolipoprotein B, lipoprotein(a), cardiovascular events, residual cardiovascular risk, nicotinic acid, simvastatin, ezetimibe, AIM-HIGH trial, metabolic syndrome, low HDL cholesterol, triglyceride elevation, ApoB/ApoA1 ratio, cardiovascular risk prediction, extended-release niacin
- MeSH
- humans, cardiovascular diseases, hypertriglyceridemia, niacin, simvastatin, triglycerides, lipoprotein(a), apolipoprotein a-i, apolipoproteins b, treatment outcome, drug therapy, combination, prospective studies, double-blind method, aged, middle aged, female, male, cholesterol, hdl, hypoalphalipoproteinemias, biomarkers, metabolic syndrome
8 autores
- John J. Albers🇺🇸University of Washington
- April E Slee
- Kevin D. O’Brien🇺🇸University of Washington
- Jennifer G. Robinson🇺🇸University of Iowa
- Moti L. Kashyap🇺🇸University of California, Irvine
- Peter O. Kwiterovich🇺🇸Johns Hopkins University
- Ping Xu
- Santica M. Marcovina🇺🇸 · autor de correspondenciaUniversity of Washington
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objectives
This study sought to examine the relationship between baseline and on-study apolipoproteins (apo) A-1 and B and lipoprotein(a) [Lp(a)] levels and the development of subsequent cardiovascular (CV) events in the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes) trial.
Background
Niacin has been reported to lower apoB and Lp(a) and to raise apoA-1.
Methods
Individuals with CV disease and low baseline levels of high-density lipoprotein cholesterol were randomized to simvastatin plus placebo or simvastatin, plus extended-release niacin ([ERN], 1,500 to 2,000 mg/day), with ezetimibe added as needed, in both groups, to maintain an on-treatment low-density lipoprotein cholesterol in the range of 40 to 80 mg/dl. Hazard ratios (HRs) were used to evaluate the relationship between levels of apoA-1, apoB, and Lp(a), and CV events in each treatment group.
Results
Baseline apoB and the apoB/apoA-I ratio were significantly predictive of CV events only for the placebo group (HR: 1.17 [p = 0.018] and HR: 1.19 [p = 0.016]). Baseline and on-study Lp(a) were predictive of CV events in both simvastatin plus placebo (baseline HR: 1.24 [p = 0.002] and on-study HR: 1.21 [p = 0.017]) and the simvastatin plus ERN group (baseline HR: 1.25 [p = 0.001] and on-study HR: 1.18 [p = 0.028]). The ERN modestly increased 1-year apoA-1 (7%), decreased apoB (13%), decreased the ApoB/ApoA-1 ratio (19%), and decreased Lp(a) 21%, but did not reduce CV events.
Conclusions
Lp(a) was associated with increased CV risk in both treatment groups indicating that it contributes to residual CV risk. However, there was no evidence that ERN reduced CV risk, despite favorable lipoprotein changes.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.